

<!--StartFragment-->RESULT 7
AEK16520
ID AEK16520 standard; protein; 235 AA.
XX
AC AEK16520;
XX
DT 16-NOV-2006 (first entry)
XX
DE Human anti-M-CSF antibody (8.10.3F), light chain.
XX
KW monoclonal antibody; light chain; 8.10.3F; neoplasm; inflammation;
KW cardiovascular disease; atherosclerosis; sepsis; asthma;
KW autoimmune disease; osteoporosis; rheumatoid arthritis; osteoarthritis;
KW cancer; cytostatic; antiinflammatory; cardiovascular-gen.;
KW antiarteriosclerotic; antibacterial; immunosuppressive; antiasthmatic;
KW osteopathic; antiarthritic; antirheumatic.
XX
OS Homo sapiens.
XX
PN WO2006096489-A2.
XX
PD 14-SEP-2006.
XX
PF 02-MAR-2006; 2006WO-US007553.
XX
PR 08-MAR-2005; 2005US-0659765P.
XX
PA (PHAA) PHARMACIA & UPJOHN CO LLC.
XX
PI Devalaraja M, Fedeckho R;
XX
DR WPI; 2006-627406/65.
DR N-PSDB; AEK16519.
XX
PT Composition useful for treating e.g. neoplasia disorder and inflammatory
PT diseases comprises antibodies which bind to human macrophage-colony
PT stimulating factor; and has reduced levels of endotoxin.
XX
PS Claim 1; SEQ ID NO 4; 80pp; English.
XX
CC The invention relates to a composition comprises at least one antibody
CC that binds to human macrophage-colony stimulating factor (M-CSF). The
CC composition is free of endotoxin. The antibody comprises an amino acid
CC sequence that is at least 90% identical to the light chain sequence given
CC as SEQ ID NO:4 in the specification, and an amino acid sequence that is
CC at least 90% identical to the heavy chain sequence given as SEQ ID NO: 2
CC the specification. Also described is a method of purification of a
CC monoclonal IgG antibody and reducing endotoxin content in a composition
CC by: contacting the antibody or the composition with an affinity
CC chromatography resin that binds to the antibody, eluting the antibody
CC from the affinity chromatography resin to form an affinity chromatography
CC eluent containing the antibody, contacting the affinity chromatography
CC eluent with an ion-exchange resin that binds to the antibody, and eluting
CC the antibody from the ion-exchange resin. The antibody is an isolated
CC human monoclonal IgG2 anti-M-CSF antibody (preferably having the heavy
CC and light chain amino acid sequences of antibody 8.10.3F). The
CC composition of the invention is useful for the treatment of M-CSF-
CC mediated disorders, including neoplasia disorders, inflammatory
CC disorders, cardiovascular disorders, atherosclerosis, sepsis, asthma,
CC autoimmune diseases, osteoporosis, rheumatoid arthritis, osteoarthritis,
CC and cancers. The composition is almost free of endotoxin. The anti-M-CSF

CC antibody exhibits both species and molecule selectivity for M-CSF that is
CC at least 100 times greater than its selectivity for granulocyte-
CC macrophage (GM)-CSF or G-CSF. This sequence represents the light chain of
CC human anti-M-CSF antibody, 8.10.3F.

XX

SQ Sequence 235 AA;

Query Match 93.3%; Score 686.5; DB 1; Length 235;
Best Local Similarity 94.4%; Pred. No. 4.7e-41;
Matches 135; Conservative 3; Mismatches 4; Indels 1; Gaps 1;

Qy 1 METPAQLLELLLLWL PDTTGEIVLTQSPGTLSSLPGERATLSCRASQVASAYLAWYQQK 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 METPAQLLELLLLWL PDTTGEIVLTQSPGTLSSLPGERATLSCRASQSVSSYLAWSYQQK 60

Qy 61 PGQAPRLLIYGASSRATDIPHRSFGSGSGTDFTLTISRLEPEDFAVYYCQQYGTSLALLTF 120
|||||:|||||:|||||:|||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 PGQAPRLLIYGASSRATGIPDRFSFGSGSGTDFTLTISRLEPEDFAVYYCQQYGSPP-LTF 119

Qy 121 GGGTKVEIKRTVAAPSVFIFPPS 143
|||||:|||||:|||||:
Db 120 GGGTKVEIKRTVAAPSVFIFPPS 142

<!--EndFragment-->